Ascletis Pharma is a clinical-stage company assembling a broad obesity portfolio that spans small molecules and peptides, with a recurring bet on long-dosing intervals. Its lead program, ASC30, is a GLP-1 receptor agonist designed for once-daily oral or once-monthly subcutaneous dosing; at ECO 2026 the company reported 7.5% placebo-adjusted weight loss at 16 weeks from a once-monthly ASC30 depot.
The pipeline widened in 2026. Alongside ASC30, Ascletis presented data on ASC47 combined with semaglutide and on ASC36, a once-monthly amylin receptor agonist. On July 5, 2026 the company filed two US FDA INDs: ASC36 and ASC36_35, a co-formulation pairing ASC36 with the GLP-1R/GIPR agonist peptide ASC35 to hit amylin, GLP-1, and GIP in one injection. In diet-induced obese rat studies ASC36 showed roughly 91% and 32% greater relative weight reduction than petrelintide and eloralintide.
Stories here track Ascletis's IND filings, conference data, and its push to make amylin a pillar of obesity treatment. See #amylin, #obesity, and #gip.
On July 5, Ascletis submitted two INDs to the FDA: ASC36, a peptide amylin receptor agonist dosed once monthly to once quarterly by injection, and ASC36_35, a co-formulation pairing ASC36 with the GLP-1R/GIPR agonist peptide ASC35. In diet-induced obese rat studies, ASC36 monotherapy showed roughly 91% and 32% greater relative body-weight reduction than petrelintide and eloralintide, and the ASC36_35 combination showed about 51% greater reduction than co-administered eloralintide plus tirzepatide. The filings push amylin biology further into the obesity race.
Ascletis Pharma will present multiple poster sessions at ECO 2026 covering programs beyond the already-presented ASC30. ASC47, an adipose-targeting thyroid hormone receptor beta (THRβ) agonist designed for muscle-preserving weight loss, demonstrated up to 111.8% greater relative weight loss when combined with semaglutide vs semaglutide monotherapy in obesity participants. ASC36, a once-monthly next-generation amylin receptor agonist peptide, posted a 32-day average observed half-life — six times longer than Zealand's petrelintide. ASC35, a once-monthly next-generation GLP-1R/GIPR dual agonist peptide, showed a 14-day average observed half-life (six times longer than tirzepatide) and 71% more relative weight loss than tirzepatide in a diet-induced obesity mouse model. Session Thursday May 14, 18:00-19:15 TRT.
Ascletis announced multiple poster presentations at the 33rd European Congress on Obesity (ECO 2026) opening May 12 in Istanbul. ASC30, a first-in-class small-molecule GLP-1R fully biased agonist developed for once-daily oral and once-monthly to once-quarterly subcutaneous dosing, will be featured across formulation, PK, and clinical-data posters. The Phase 2 13-week study previously reported 7.7% placebo-adjusted weight loss at 60 mg oral dosing; the once-monthly subQ depot formulation achieved 7.5% placebo-adjusted weight loss at 16 weeks after three monthly doses, with topline T2D Phase 2 data expected Q3 2026. The subQ depot angle directly challenges Pfizer's MET-097i monthly thesis with a different mechanism (small-molecule GLP-1R biased agonist vs ultra-long-acting peptide).